London, UK – 5 September 2023 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary patient-centric human extracellular matrix (ECM) platform, today announces the appointment of Christopher (Chris) Stevenson, Ph.D. as Chief Scientific Officer (CSO). In this new role, Chris will be responsible […]
London, UK – 9 May 2023 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today announces the appointment of Sonia Quaratino, M.D., PH.D., to its Board of Directors, as an independent non-executive director. Dr. Quaratino has over […]
London, UK – 5 October 2022 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today celebrated its expansion and growth with a Grand Opening at its new facilities in White City, West London. Engitix purpose-designed mixed-use headquarters and R&D […]
Collaboration combines Engitix’s unique human extracellular matrix (ECM) platform with Takeda’s expertise in gastroenterology research and development (R&D) and commercialisation.
$54m series A financing co-led by existing investor Netherton Investments (a fund investing on behalf of Mike Platt) and new investor Dompé farmaceutici S.P.A (an Italian and US-based biopharmaceutical company)
London, UK – 4 May 2021 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today announced that it has appointed Dr Mike Burbridge, as Vice President, Oncology & Immuno-oncology. Dr […]
Company is on expansion curve with two new appointments and recent move to larger facilities London, UK – 23 Feb, 2021 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours and with two significant partnerships based on its pioneering proprietary human extracellular matrix (ECM) drug discovery platform, today […]
London, UK – December 15, 2020 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based on its proprietary human extracellular matrix (ECM) platform, today announced that it is relocating its headquarters and operations to WestWorks, White City Place (WCP). The move follows […]
London, UK – December 1, 2020 – Engitix Ltd (‘Engitix’), a biotechnology company with a portfolio of programmes in fibrosis and solid tumours and two significant partnerships based upon its proprietary human extracellular matrix (ECM) platform, today announced the appointment of Eduardo Bravo as Chairman of its Board of Directors. Eduardo has over 25 years […]
Collaboration combines Engitix’s unique ECM platform with Takeda’s expertise in gastroenterology research and development (R&D) and commercialisation London, UK – 25 August 2020 – Engitix Ltd (‘Engitix’), a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM) platform, today entered into a licensing and collaboration agreement […]
